Keyword: Ajovy

Teva is riding high after a strong launch for Austedo. But is "tenfold" patient growth in one of its indications possible? Analysts aren't so sure.

Amgen had a head start on the CGRP race with its first-in-class approval for Aimovig, but now it's slipped under 50% total market share.

Debt-rating firm Moody's revised its Teva outlook from "stable" to "negative" as the company deals with multiple challenges.

Hard on the heels of its CGRP migraine competitors, Eli Lilly’s Emgality has been looking for a leg up. Solid data in preventing migraines as a follow-up treatment could do the trick.

Sales of Lilly’s Emgality have lagged behind rivals. And to bring payers on board, Lilly is deploying a full-court press with new patient data.

Biohaven could soon go up against large drugmakers' CGRP injectables Aimovig, Ajovy and Emgality with its oral drug rimegepant.

Facing Amgen's first-to-market advantage and Eli Lilly's marketing muscle, Teva's migraine drug Ajovy is relying on an underdog-style promo push.

So far in Teva's extensive cost-cutting drive, 10,000 people have left the company, CEO Kåre Schultz said Thursday.

Teva's decision to abandon the cluster headache market gives Eli Lilly and its CGRP med Emgality a shot at dominating the indication.

Amgen wants to exit its collaboration with Novartis on migraine prevention drug Aimovig.